Evaluating the role of photodynamic therapy in the management of pancreatic cancer

Lasers in Surgery and Medicine

Volumn 16, Issue 1, 1995, Pages 84-92

  Moesta, K Thomas ^a   Schlag, Peter ^b   Douglass, Harold O ^a   Mang, Thomas S ^a,c  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^c UNIVERSITY AT BUFFALO   (United States)

Author keywords

adjuvant treatment; palliative treatment; pancreatic neoplasms; photochemotherapy

Indexed keywords

FLUOROURACIL; IODINE 125; PHOTOFRIN;

CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; COMPLICATION; HUMAN; NONHUMAN; PANCREAS CANCER; PANCREAS RESECTION; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; REVIEW;

ANIMAL; COMBINED MODALITY THERAPY; HAMSTERS; HUMAN; MICE; PALLIATIVE CARE; PANCREATIC NEOPLASMS; PHOTOCHEMOTHERAPY; SURVIVAL RATE;

EID: 0028795298     PISSN: 01968092     EISSN: 10969101     Source Type: Journal    
DOI: 10.1002/lsm.1900160112     Document Type: Review

References (81)

1. Cancer statistics, 1990
2. Cancer statistics, 1986
3. Aktuelle Aspekte des Pankreaskazinoms
4. Patterns of failure after curative resection of pancreatic cancer
5. Collective review of small carcinomas of the pancreas
6. Small carcinoma of the pancreas: Clinical and pathological evaluation of 17 patients
7. Cancer of the pancreas: Diagnostic accuracy and survival statistics
8. Cancer of the pancreas: 50 years of surgery
9. Evaluation of palliative surgical procedures in unresectable pancreatic cancer
10. Chemothera‐phy for advanced pancreatic cancer: A comparison of 5‐FU, Adrimaycin and Mitomycin C
11. Gastrointestinal Tumer Study Group. Ifosfamide is an inactive substance in the treatment of pancreatic carcinoma
12. A phase III trial on the therapy of advanced pancreatic carcinoma: Evaluations of the Mallison regime
13. Chemotherapy of pancreatic carcinoma (review)
14. A phase II multi‐instutitional trial of low‐dose N‐(phosphonacetyl)‐L‐aspartate and high‐dose 5‐FU as a short‐term infusion in the treatment of adeno‐carcinoma of the pancreas
15. Radiotherapy of unresectable pancreatic carcinoma: A six‐year experience with 104 patients
16. External beam versus intraoperative and external beam irradiation for locally advanced pancreatic cancer
17. Iodine‐125 implant and external beam irradiation in patients with localized pancreatic carcinoma
18. Morbidity and mortality associated with intraoperative radiotherapy
19. Intraoperative radiation therapy of pancreatic carcinoma: A report of RTOG‐8505. Radiation Therapy Oncology Group
20. Treatment of primary unresectable carcinoma of the pancreas with I‐125 implantation
21. Interstitial brachytherapy for pancreatic cancer: Report of seven cases treated with 1251 and a review of the literature
22. I‐125 interstitial implant, precision high‐dose external beam therapy, and 5‐FU for unresectable adenocarcinoma of the pancreas and the biliary tree
23. Hyperfractionated radiation for unresectable localized adenocarcinoma of the pancreas: The Gastrointestinal Tumor Study Group experience
24. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose radiation alone, moderate dose radiation + 5‐FU, and high dose radiation + 5‐FU
25. Localized unresectable pancreatic cancer
26. Attempted curative resection of ductal carcinoma of the pancreas—review of the Mayo Clinic experience
27. Comparison of conventional surgical resection, radioactive implantation, and bypass procedure for exocrine carcinoma of the pancreas
28. Surgical principles for pancreatic cancer: Regional total and subtotal pancreatectomy
29. Radical pancreatectomy for ductal cell carcinoma of the head of the pancreas
30. Regional pancreatectomy for cancer of the pancreas, ampulla and other related sites
31. Clinical experience with regional pancreatectomy for adenocarcinoma of the pancreas
32. Metabolic consequences of (regional) total pancreatectomy
33. Survival after pancreatoduodenectomy. 118 consecutive resections without an operative mortality
34. The results and problems of extensive radical surgery for carcinoma of the head of the pancreas
35. Pancreatic cancer: Adjuvant combined radiation and chemotherapy following curative resection
36. Adjuvant therapy of resected adenocarcinoma of the pancreas
37. New surgical approaches to pancreatic cancer
38. Photosensitizers: Therapy and detection of malignant tumors
39. Photodynamic therapy of cancer
40. Photodynamic therapy for the treatment of cancer: current status and advances
41. In situ evidence for the involvement of superoxide anions in cutaneous porphyrin photosensitization
42. Drug and light dose dependence of photodynamic therapy: A study of tumor and normal tissue response
43. Differential cell photosensitivity following porphyrin photodynamic therapy
44. Tumor destruction and kinetics of tumor cell death in two experimental mouse tumors following Photodynamic Therapy
45. Determination of H‐3‐ and C‐14‐ hematoporphyrin derivative distribution in malignant and normal tissue
46. Aluminum sulfonated phtallocyanine distribution in rodent tumors of the colon, brain and pancreas
47. Photodynamic therapy to scientists and clinicians—One world or two?
48. Photodynamic therapy in the treatment of pancreatic carcinoma: dihematoporphyrin ether uptake and photobleaching kinetics
49. Hematoporphyrin derivative uptake and photodynamic therapy in pancreatic carcinoma
50. Studies on the absence of photodynamic mechanism in the normal pancreas
51. Photodynamic therapy of tumors: Definition of PDT dose and response
52. Clinical experience with PDT:A 5‐yearstudy
53. Photodynamic therapy of neoplas‐tic disease
54. Optimization of photo‐dynamic therapy light dose distribution and treatment volume by multi‐fiber insertions
55. Interaction of interstitial photodynamic therapy and interstitial hyperthermia in a rat rhabdomyosarcoma: A pilot study
56. Optical dosimetry for interstitial photodynamic therapy
57. Photodynamic therapy of malignant brain tumors
58. In vivo measurement of the optical interaction coefficients of human tumors at 630 nm
59. Dose measurements in photodynamic therapy of cancer
60. Distribution and elimination of Photofrin II in mice
61. Cancer of the pancreas induced in the Syrian golden hamster
62. Transplantation of azazerine‐induced carcinomas at pancreas in rats
63. Intra‐abdominal applications on hemaotporphyrin photoradiation therapy
64. Photodynamic action of rose ben‐gal on isolated rat pancreatic acini: Stimulation of amy‐lase release
65. Jejunal blood flow after exposure to light in rats injected with hematoporphyrin derivative
66. Photo‐dynamic therapy for early gastric cancer using a gold vapor laser
67. Evaluation of photodynamic therapy in advanced gastrointestinal cancer
68. The contrasting mechanisms of colonic collagen damage between photodynamic therapy and thermal injury
69. Photodynamic therapy to treat tumors of the extrahepatic ducts
70. Morphological changes of tumor microvasculature following hematoporphyrin derivative sensitized photodynamic therapy
71. Experimental study of intra‐abdominal photodynamic therapy
72. Systemic im‐munosuppression induced by peritoneal photodynamic therapy
73. Photodynamic therapy of the canine peritoneum: normal tissue response to intraperitoneal and intravenous Photofrin followed by 630 nm light
74. Photodynamic therapy of ascites tumours within the peritoneal cavity
75. Technique of photodynamic therapy for disseminated intraperitoneal malignant neoplasms
76. Surgical palliation for pancreatic cancer: The UCLA experience
77. Unresectable pancreatic cancer: What is the optimal procedure?